With the increasing use of osimertinib as first-line therapy, use of 18F-FDG PET/CT parameters for evaluating the response of patients with NSCLC and EGFR mutations to osimertinib warrants further investigation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.